{
  "PMC": "5823123",
  "DOI": "10.1100/tsw.2009.166",
  "PMID": "20024517",
  "PMCID": "PMC5823123",
  "title": "Trastuzumab resistance: role for Notch signaling.",
  "year": 2009,
  "source_url": "https://europepmc.org/article/PMC/PMC5823123",
  "source": "MED",
  "abstract_text": "Epidermal growth factor receptor-2 (ErbB-2/HER2) is a potent breast oncogene that has been shown to be amplified in 20% of breast cancers. Overexpression of ErbB-2 predicts for aggressive tumor behavior, resistance to some cytotoxic and antihormonal therapies, and poor overall survival. Trastuzumab, the humanized, monoclonal antibody directed against ErbB-2 has shown tremendous efficacy and improved overall survival for women when combined with a taxane-based chemotherapy. However, resistance to trastuzumab remains a major concern, most notably in women with metastatic breast cancer. Numerous mechanisms that include overexpression of alternate receptor tyrosine kinases and/or loss of critical tumor suppressors have been proposed in the last several years to elucidate trastuzumab resistance. Here we review the many possible mechanisms of action that could contribute to resistance, and novel therapies to prevent or reverse the resistant phenotype. Moreover, we provide a critical role for Notch signaling cross-talk with overlapping or new signaling networks in trastuzumab-resistant breast.",
  "full_text": "ScientificWorldJournal ScientificWorldJournal TSWJ The Scientific World Journal 2356-6140 1537-744X TheScientificWorldJOURNAL 5823123 20024517 135863 10.1100/tsw.2009.166 Review Article Trastuzumab Resistance: Role for Notch Signaling Mehta Kinnari 1 Osipo Clodia 1 2 3 * 1 Molecular Biology Program, Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, IL, USA 2 Department of Pathology, Oncology Institute, Cardinal Bernardin Cancer Center, Maywood, IL, USA 3 Molecular and Cellular Biochemistry Program, Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, IL, USA *Clodia Osipo: cosipo@lumc.edu Academic Editor: John D. Scott 2009 16 12 2009 9 1438 1448 03 6 2009 08 12 2009 09 12 2009 Copyright Â© 2009 Kinnari Mehta and Clodia Osipo. 2009 This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Epidermal growth factor receptor-2 (ErbB-2/HER2) is a potent breast oncogene that has been shown to be amplified in 20% of breast cancers. Overexpression of ErbB-2 predicts for aggressive tumor behavior, resistance to some cytotoxic and antihormonal therapies, and poor overall survival. Trastuzumab, the humanized, monoclonal antibody directed against ErbB-2 has shown tremendous efficacy and improved overall survival for women when combined with a taxane-based chemotherapy. However, resistance to trastuzumab remains a major concern, most notably in women with metastatic breast cancer. Numerous mechanisms that include overexpression of alternate receptor tyrosine kinases and/or loss of critical tumor suppressors have been proposed in the last several years to elucidate trastuzumab resistance. Here we review the many possible mechanisms of action that could contribute to resistance, and novel therapies to prevent or reverse the resistant phenotype. Moreover, we provide a critical role for Notch signaling cross-talk with overlapping or new signaling networks in trastuzumab-resistant breast. ErbB-2 trastuzumab Notch-1 GSI breast cancer",
  "plain_text": "Epidermal growth factor receptor-2 (ErbB-2/HER2) is a potent breast oncogene that has been shown to be amplified in 20% of breast cancers. Overexpression of ErbB-2 predicts for aggressive tumor behavior, resistance to some cytotoxic and antihormonal therapies, and poor overall survival. Trastuzumab, the humanized, monoclonal antibody directed against ErbB-2 has shown tremendous efficacy and improved overall survival for women when combined with a taxane-based chemotherapy. However, resistance to trastuzumab remains a major concern, most notably in women with metastatic breast cancer. Numerous mechanisms that include overexpression of alternate receptor tyrosine kinases and/or loss of critical tumor suppressors have been proposed in the last several years to elucidate trastuzumab resistance. Here we review the many possible mechanisms of action that could contribute to resistance, and novel therapies to prevent or reverse the resistant phenotype. Moreover, we provide a critical role for Notch signaling cross-talk with overlapping or new signaling networks in trastuzumab-resistant breast."
}
